Page 76 - 2022_03-Haematologica-web

O. Benjamini et al.
cohort neither gender nor IGHV mutation status was a statistically significant factor for positive response. In addition, by examining the correlation of complete blood count results with response rate, we found that both abnormal hemoglobin and platelet levels were associated with a low response rate.
During the course of the study and in the 3-month observation period after the second dose of vaccine only three out of 400 vaccinated patients developed COVID- 19 infection. One patient acquired the infection between the first dose and the second dose (3 weeks) and two patients 14 days and 24 days after the second dose. All three of them recovered uneventfully.
Several studies have indicated that not only does the tumor response play a role in the immune response after vaccination with BNT162b2 mRNA COVID-19 vaccine, but that other factors are also involved. Recent research showed that two doses of 1 mg or 50 mg of BNT162b1 can
Table 4. Multivariate analysis of serological response in patients with chronic lymphocytic leukemia.
Variable
Age >70 years
Male
CIRS score ≥6
Prior therapy 1st line
Prior therapy ≥ 2nd line
Time since last anti-
CD20 antibodies ≤12 months
IgG <700 mg/dL
IgM <40 mg/dL
IgA <80 mg/dL Ongoing BTK inhibitor Ongoing BCL2 inhibitor
Odds ratio
0.6543 0.9315 1.0697 0.3013 0.1246
0.0874
0.7358
0.3944
0.6052
0.0577
0.1516
95% CI
(0.4323-0.9867) (0.6138-1.4131) (0.3281-3.533) (0.0208-3.0227) (0.0082-1.2373)
(0.0046-0.5103)
(0.4199-1.2906)
(0.2379-0.6493)
(0.3555-1.0278)
(0.0069-0.3195)
(0.005-2.22)
P-value 0.0444
0.7385 0.9104 0.3243 0.0891
0.0256 0.0012 <.001 0.0631 0.0029 0.1989
95% CI: 95% confidence interval; CIRS: Cumulative Illness Rating Scale.
Figure 3. Vaccine efficacy according to treatment. Vaccine response rate by treatment status, by treatment type and treatment timing and response to vaccine in patients who were treated or are currently being treated with BKT inhibitors or BCL2 inhibitors. mo: months; BKTi: BKT inhibitor; BCL2i: BCL2 inhibitor.
632
haematologica | 2022; 107(3)